Background {#Sec1}
==========

Colorectal cancer (CRC) is the third most common type of cancer and the second leading cause of cancer-related mortality in Western countries \[[@CR1]\]. The prognosis of patients with CRC depends on the tumor stage at the time of diagnosis. However, over 57% of patients have regional or distant spread of tumor cells at the time of diagnosis \[[@CR2]\]. The pathogenesis of CRC usually follows a stepwise progression from benign polyp to invasive adenocarcinoma. In colorectal carcinogenesis, the unique molecular and genetic changes that occur within cells result in a specific CRC phenotype. This phenotype is associated with variable tumor behaviors that are relevant to the prognosis and the response to specific therapies. As a result, the term "CRC" no longer refers to a single disease, but rather a heterogeneous group of diseases caused by differential genetic/epigenetic backgrounds. In this respect, many ongoing studies are aimed at assessing biomarkers as potential predictors of prognosis or response to therapy, which will most likely lead to the individualized management of the disease.

Tumor angiogenesis is important to tumor growth, as evidenced by results showing that tumor growth is dependent on angiogenesis. Furthermore, tumors are able to produce diffusible angiogenic molecules \[[@CR3]\], including vascular endothelial growth factor (VEGF). VEGF is a key regulator of angiogenesis with several functions that serve to enhance tumor progression. These functions include enhancing vascular permeability, inducing endothelial cell migration and division, inducing serine protease activity, inhibiting either the apoptosis of endothelial cells or maturation of dendritic cells, and inducing angiogenesis \[[@CR4], [@CR5]\]. The human *VEGF* gene is located on chromosome 6 and organized into eight exons and seven introns, which encode several different isoforms due to alternative splicing. There are five well-studied *VEGF* polymorphisms that have been linked to CRC: -2578C \> A, -1498T \> C, -1154G \> A, -634G \> C, and 936C \> T. However, their genetic associations with CRC have been inconsistent \[[@CR6]\]. Recent papers have shown some clinical impacts of polymorphisms in the 3′-UTR of certain genes, which may potentially bind to specific miRNAs in various cancers \[[@CR7]--[@CR10]\]. However, variants in the *VEGF* 3′-UTR have not been studied.

The metabolic syndrome (MetS) is a portfolio of metabolic disorders, including abdominal obesity, increased blood pressure (BP), abnormal glucose metabolism, and dyslipidemia \[[@CR11]\]. Previous reports show that components of MetS are associated with CRC susceptibility \[[@CR12], [@CR13]\]. A previous study found a 35% increased CRC risk associated with high BP \[[@CR14]\] and there was a similar finding in another prospective epidemiologic study \[[@CR15]\]. Adult-onset diabetes mellitus (DM) has generally been associated with a higher risk of CRC \[[@CR16]--[@CR20]\] and elevated blood glucose levels correlated with a significantly elevated CRC risk (Relative risk \[RR\] = 1.80) \[[@CR21]\]. However, gene-environment combined effects of MetS for CRC susceptibility have been infrequently found in previous published database.

In the *VEGF* gene, there are four known 3′-UTR polymorphisms (936C \> T \[rs3025039\], 1451C \> T \[rs3025040\], 1612G \> A \[rs10434\], 1725G \> A \[rs3025053\]). The *VEGF* 1451TT genotype presented a significant log-rank *p* value in non-small-cell lung cancer survival \[[@CR22]\]. The *VEGF* 1612A allele was associated with increased gastric cancer risk \[[@CR23]\]. The 936C \> T polymorphism and its link to CRC susceptibility have been published by our laboratory and others \[[@CR6], [@CR24]\]. The other three single nucleotide polymorphisms (SNPs) in the *VEGF* 3′-UTR, 1451C \> T, 1612G \> A, and 1725G \> A, are poorly understood in the context of their genetic contributions to CRC susceptibility. The purpose of this study was to investigate whether these polymorphisms of *VEGF* 3′-UTR correlate with CRC susceptibility and the genetic contributions are modified by the presence of MetS.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

We conducted a case--control study of 850 individuals. Four hundred and fifty patients diagnosed with CRC at CHA Bundang Medical Center (Seongnam, South Korea) were enrolled from June 2004 to January 2009. This study only included CRC patients who had undergone surgical resection with a curative intent and who had histologically confirmed adenocarcinoma. Within the CRC cohort, 264 consecutive patients with colon cancer and 186 consecutive patients with rectal cancer underwent primary surgery. Tumor staging of CRCs was performed according to the sixth edition of the American Joint Committee on Cancer (AJCC) staging manual. The control group consisted of 400 individuals randomly selected following a health screening. This screening excluded patients with a history of cancer. Individuals were diagnosed with MetS if they possessed three or more of the following five risk factors: body mass index (BMI) ≥25.0 kg/m^2^; triglycerides (TG) ≥150 mg/dL; high density lipoprotein-cholesterol (HDL-C) \<40 mg/dL for men or \<50 mg/dL for women; BP ≥130/85 mmHg or currently taking anti-hypertension medication; and fasting blood sugar (FBS) ≥100 mg/dL or currently taking hypoglycemic medication. All study subjects were ethnic Koreans and provided written informed consent. The study protocol was approved by the Institutional Review Board of CHA Bundang Medical Center, Seongnam, South Korea.

Phenotype measurements {#Sec4}
----------------------

Anthropometric measurements included BMI. Systolic and diastolic BP of subjects were measured in the seated position after 10 min of rest. For measurements of physiological parameters, 3 ml blood was obtained after fasting overnight. The hexokinase method was employed to measure FBS levels; samples were analyzed in duplicate by an automated analyzer (TBA 200FR NEO, Toshiba Medical Systems, Tokyo, Japan). TG and HDL-C levels were determined by enzymatic colorimetric methods using commercial reagent sets (TBA 200FR NEO, Toshiba Medical Systems).

Genotyping {#Sec5}
----------

DNA was extracted from leukocytes using a G-DEX™ II Genomic DNA Extraction kit (Intron Biotechnology, Seongnam, Korea) according to the manufacturer's instructions. *VEGF* genotypes were analyzed by TaqMan allelic discrimination analysis. Genotyping of the *VEGF* 1451C \> T, *VEGF* 1612G \> A, and *VEGF* 1725G \> A polymorphisms was determined using real-time polymerase chain reaction (PCR) (RG-6000, Corbett Research, Australia) for allelic discrimination. Primers and TaqMan probes were designed using Primer Express Software (version 2.0) and synthesized and supplied by Applied Biosystems (Foster City, CA, USA). The reporter dyes used were FAM and JOE. The primer sequences for amplification are as follows: *VEGF* 1451C \> T: forward 5′- ACG GAC AGA AAG ACA GAT CAC AG -3′ and reverse 5′- CCC AAA GCA CAG CAA TGT C -3′. The selected probes were 5′-FAM- TGA GGA CAC CGG CTC TGA CC -TAMRA-3′ (C allele detecting probe) and 5′-JOE- TGA GGA CAC TGG CTC TGA CC -TAMRA-3′ (T allele detecting probe). *VEGF* 1612G \> A: forward 5′- TTC GCT TAC TCT CAC CTG CTT C -3′ and reverse 5′- GCT GTC ATG GGC TGC TTC T -3′. The selected probes were 5′-FAM- CCC AGG AGG CCA CTG GCA -TAMRA-3′ (G allele detecting probe) and 5′-JOE- CCC AGG AGA CCA CTG GCA -TAMRA-3′ (A allele detecting probe). *VEGF* 1725G \> A: forward 5′- CAT GAC AGC TCC CCT TCC T -3′ and reverse 5′- TGG TTT CAA TGG TGT GAG GAC -3′. The selected probes were 5′-FAM- CTT CCT GGG GTG CAG CCT AA -TAMRA-3′ (G allele detecting probe) and 5′-JOE- CTT CCT GGG ATG CAG CCT AA -TAMRA-3′ (A allele detecting probe). For each polymorphism, 30% of the PCR assays were randomly selected and repeated, followed by DNA sequencing, to validate the experimental findings. Sequencing was performed using an ABI 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA, USA). The concordance of the quality control samples was 100%.

Quantitative real-time PCR {#Sec6}
--------------------------

To perform quantitative real-time PCR (qRT-PCR), total RNA was extracted from 47 tumor and tumor-adjacent tissues from 47 CRC patients by using TRIzol Reagent (Invitrogen, Grand Island, NY, USA) according to the manufacturer's instructions. cDNA was made from total RNA with the SuperScript III First-Strand Synthesis System (Invitrogen, Grand Island, NY, USA). Measurement of the VEGF mRNA was determined using real-time PCR (RG-6000, Corbett Research, Australia). The expression level of VEGF mRNA in 47 tumor and tumor-adjacent tissues was compared by a comparative C~T~ (2^-ΔΔC^~T~) method with housekeeping internal control, 18 s rRNA. The primer sequences for amplification are as follows: 18 s rRNA: forward 5′- AAC TTT CGA TGG TAG TCG CCG -3′ and reverse 5′- CCT TGG ATG TGG TAG CCG TTT -3′. VEGF: forward 5′- TGA GCT TCC TAC AGC ACA AC -3′ and reverse 5′- ATT TAC ACG TCT GCG GAT CTT -3′.

Statistical analysis {#Sec7}
--------------------

To analyze baseline characteristics, odds ratios (ORs) and 95% confidence intervals (95% CIs) from univariate logistic regression were used to compare patient and control baseline data. Genetic associations of *VEGF* 1451C \> T, 1612G \> A, and 1725G \> A polymorphisms with MetS and CRC susceptibility were calculated using adjusted odds ratios (AORs) and 95% CIs from multivariate logistic regression. The variables age, gender, and MetS risk factors were selected as adjustment variables. To estimate MetS and CRC risk, we used three genetic susceptibility models: additive, dominant, and recessive. All *VEGF* 3′-UTR genotypes were converted into numeric values for logistic regression according to their genotypes. Wild homozygotes were assigned "0" in all models. Heterozygotes were assigned "1" in additive and dominant models and "0" in the recessive model. Mutant homozygotes were assigned "1" in dominant and recessive models and "2" in the additive model. Gene-environment interaction analysis was performed using the open-source multifactor dimensionality reduction (MDR) software package (v.2.0) available from <http://www.epistasis.org>. The comparisons of relative VEGF mRNA expression were analyzed by Mann--Whitney, Krusukal-Wallis, and Wilcoxon signed rank tests. Analyses were performed using GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, CA, USA) and Medcalc version 12.7.1.0 (Medcalc Software, Mariakerke, Belgium). Haplotypes for multiple loci were estimated using the expectation-maximization algorithm with SNPAlyze (Version 5.1; DYNACOM Co, Ltd, Yokohama, Japan).

Results {#Sec8}
=======

In this study, we collected data for 450 CRC patients (264 colon cancer \[CC\] and 186 rectal cancer \[RC\] patients), including 212 men and 238 women. Both CC and RC groups have higher portion of tumor size ≥5 cm and tumor node metastasis (TNM) stage II/III (Table [1](#Tab1){ref-type="table"}). The presence of MetS was associated with CRC susceptibility (CC group: OR = 1.90; 95% CI = 1.35 - 2.66; *p* \< .001; RC group: OR = 2.07; 95% CI = 1.43 - 3.01; *p* \< .001). Of MetS risk factors, lower HDL-C (\<40 mg/dL for men or \<50 mg/dL for women) strongly contributed to CC and RC risk (CC group: OR = 3.09; 95% CI = 2.18 - 4.37; *p* \< .001; RC group: OR = 3.40; 95% CI = 2.32 - 4.97; *p* \< .001). Table [2](#Tab2){ref-type="table"} shows the distributions of genotypes and haplotypes for *VEGF* 1451C \> T, 1612G \> A, and 1725G \> A polymorphisms stratified by the presence of MetS. The *VEGF* 3′-UTR genotype frequencies of controls were consistent with the Hardy-Weinberg equilibrium. Table [3](#Tab3){ref-type="table"} presents AOR values for MetS, CC, and RC risk by *VEGF* 3′-UTR polymorphisms. *VEGF* 1451C \> T was significantly associated with RC risk (Dominant model: AOR = 1.58; 95% CI = 1.09 - 2.28; *p* = 0.015) whereas *VEGF* 1725G \> A correlated with MetS risk (Dominant model: AOR = 1.61; 95% CI = 1.06 - 2.46; *p* = 0.026). As a similar pattern, in haplotype analysis, *VEGF* 1451T/1612G/1725G contributed to RC risk (AOR = 1.40; 95% CI = 1.03 - 1.92; *p* = 0.030) while *VEGF* 1451C/1612A/1725A was involved with MetS risk (AOR = 1.54; 95% CI = 1.02 - 2.34; *p* = 0.041).Table 1**Baseline characteristics in colorectal cancer patients and control subjects**CharacteristicsControlCCOR (95% CI)***p***RCOR (95% CI)***p***N400264186Age (mean±SD)60.89 ± 11.7261.85 ± 12.851.01 (0.99 - 1.02)0.32062.33 ± 11.461.01 (1.00 - 1.03)0.165Gender (male), n (%)170 (42.5)124 (47.0)1.20 (0.88 - 1.64)0.25788 (47.3)1.21 (0.86 - 1.72)0.275Metabolic syndrome, n (%)95 (23.8)98 (37.1)1.90 (1.35 - 2.66)\<.00173 (39.2)2.07 (1.43 - 3.01)\<.001Anti-HTN drug or BP ≥ 130/85 mmHg, n (%)157 (39.3)159 (60.2)2.34 (1.71 - 3.22)\<.001120 (64.5)2.81 (1.96 - 4.04)\<.001Anti-DM drug or FBS ≥ 100 mg/dl, n (%)166 (41.5)149 (56.4)1.83 (1.33 - 2.50)\<.001104 (55.9)1.79 (1.26 - 2.54)0.001TG ≥ 150 mg/dl, n (%)135 (33.8)67 (25.4)0.67 (0.47 - 0.94)0.02246 (24.7)0.65 (0.44 - 0.95)0.029BMI ≥ 25 kg/m^2^, n (%)93 (23.3)65 (24.6)1.08 (0.75 - 1.55)0.68551 (27.4)1.25 (0.84 - 1.85)0.276HDL-C \< 40(male)/50(female) mg/dl, n (%)78 (19.5)113 (42.8)3.09 (2.18 - 4.37)\<.00184 (45.2)3.40 (2.32 - 4.97)\<.001Tumor size\<5 cm-94 (35.6)\--87 (46.8)\--≥5 cm-170 (64.4)\--99 (53.2)\--TNM stage, n (%)I-22 (8.3)\--20 (10.8)\--II-118 (44.7)\--71 (38.2)\--III-94 (35.6)\--79 (42.5)\--IV-30 (11.4)\--16 (8.6)\--Colon cancer (CC), Rectal cancer (RC), Odds ratio (OR), Confidence interval (CI), Standard deviation (SD), Blood pressure (BP), Fasting blood sugar (FBS), Hypertension (HTN), Diabetes mellitus (DM), Triglycerides (TG), Body mass index (BMI), High density lipoprotein-cholesterol (HDL-C), Tumor node metastasis (TNM). ORs and *p* values were calculated by univariate logistic regression.Table 2**Genotype and haplotype frequencies of** ***VEGF*** **3′-UTR polymorphisms**Without MetSWith MetSGenotype/HaplotypeControl (n = 305)CC (n = 166)RC (n = 113)Control (n = 95)CC (n = 98)RC (n = 73)*VEGF* 1451CC209 (68.5)108 (65.1)64 (56.6)65 (68.4)72 (73.5)45 (61.6)*VEGF* 1451CT81 (26.6)50 (30.1)43 (38.1)29 (30.5)23 (23.5)27 (37.0)*VEGF* 1451TT15 (4.9)8 (4.8)6 (5.3)1 (1.1)3 (3.1)1 (1.4)HWE*-p*0.0590.4830.7240.2510.4930.167*VEGF* 1612GG213 (69.8)127 (76.5)87 (77.0)67 (70.5)68 (69.4)54 (74.0)*VEGF* 1612GA83 (27.2)36 (21.7)21 (18.6)27 (28.4)29 (29.6)18 (24.7)*VEGF* 1612AA9 (3.0)3 (1.8)5 (4.4)1 (1.1)1 (1.0)1 (1.4)HWE*-p*0.7910.8090.0220.3360.2710.714*VEGF* 1725GG278 (91.1)147 (88.6)96 (85.0)81 (85.3)79 (80.6)61 (83.6)*VEGF* 1725GA27 (8.9)19 (11.4)17 (15.0)14 (14.7)19 (19.4)12 (16.4)*VEGF* 1725AA0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)HWE*-p*0.4190.4340.3870.4380.2880.444*VEGF* 1451C/1612G/1725G398 (65.2)221 (65.6)140 (61.9)130 (68.4)134 (68.4)96 (65.8)*VEGF* 1451T/1612G/1725G111 (18.2)66 (19.9)55 (24.3)31 (16.3)29 (14.8)29 (19.9)*VEGF* 1451C/1612A/1725G74 (12.1)26 (7.8)14 (6.2)15 (7.9)14 (7.1)9 (6.2)*VEGF* 1451C/1612A/1725A27 (4.4)16 (4.8)17 (7.5)14 (7.4)17 (8.7)11 (7.5)*VEGF* 1451C/1612G/1725A0 (0.0)3 (0.9)0 (0.0)0 (0.0)2 (1.0)1 (0.7)Vascular endothelial growth factor (VEGF), Colon cancer (CC), Rectal cancer (RC), Metabolic syndrome (MetS), Hardy-Weinberg equilibrium (HWE).Table 3**Adjusted odds ratios for metabolic syndrome, colon cancer, and rectal cancer risks according to** ***VEGF*** **3′-UTR variants**MetS riskCC riskRC riskGenotype/HaplotypeModelWild typeAOR (95% CI)\****p***AOR (95% CI)\*\****p***AOR (95% CI)\*\****p****VEGF* 1451C \> TAdditiveCC0.80 (0.61 - 1.05)0.1051.05 (0.79 - 1.39)0.7421.40 (1.03 - 1.91)0.031DominantCC0.85 (0.62 - 1.16)0.2951.04 (0.74 - 1.46)0.8131.58 (1.09 - 2.28)0.015RecessiveCC0.36 (0.14 - 0.96)0.0411.16 (0.53 - 2.57)0.7091.12 (0.45 - 2.80)0.804*VEGF* 1612G \> AAdditiveGG1.02 (0.76 - 1.36)0.9200.82 (0.59 - 1.12)0.2160.83 (0.58 - 1.18)0.304DominantGG1.11 (0.80 - 1.54)0.5210.81 (0.57 - 1.15)0.2390.74 (0.50 - 1.11)0.149RecessiveGG0.38 (0.11 - 1.33)0.1300.68 (0.21 - 2.21)0.5211.48 (0.52 - 4.19)0.458*VEGF* 1725G \> AAdditiveGG1.61 (1.06 - 2.46)0.0261.34 (0.83 - 2.16)0.2351.51 (0.90 - 2.55)0.118DominantGG1.61 (1.06 - 2.46)0.0261.34 (0.83 - 2.16)0.2351.51 (0.90 - 2.55)0.118RecessiveGG\-\-\-\-\--*VEGF* 1451C/1612G/1725GOthers1.14 (0.92 - 1.43)0.2321.04 (0.82 - 1.31)0.7620.87 (0.67 - 1.12)0.279*VEGF* 1451T/1612G/1725GOthers0.80 (0.61 - 1.05)0.1011.05 (0.79 - 1.41)0.7351.40 (1.03 - 1.92)0.030*VEGF* 1451C/1612A/1725GOthers0.73 (0.50 - 1.07)0.1110.69 (0.47 - 1.02)0.0660.56 (0.34 - 0.90)0.017*VEGF* 1451C/1612A/1725AOthers1.54 (1.02 - 2.34)0.0411.12 (0.69 - 1.80)0.6521.42 (0.86 - 2.36)0.170Adjusted odds ratio (AOR), Confidence interval (CI), Metabolic syndrome (MetS), Colon cancer (CC), Rectal cancer (RC), Vascular endothelial growth factor (VEGF). \*AORs and *p* values were adjusted by age and gender. \*\*AORs and *p* values were adjusted by age, gender, and MetS risk factors.

Because cancer risk is determined by a complex interplay of genetic and environmental factors, we calculated gene-environment combined effects between MetS and *VEGF* 3′-UTR polymorphisms. Preferentially, we sought to determine whether the contribution of *VEGF* 3′-UTR genetic variants to CRC susceptibility varied with the presence of MetS (Table [4](#Tab4){ref-type="table"}). The significant involvements of *VEGF* 1451C \> T (Dominant model: AOR = 1.67; 95% CI = 1.07 - 2.61; *p* = 0.023) and *VEGF* 1451T/1612G/1725G (AOR = 1.45; 95% CI = 1.00 - 2.09; *p* = 0.047) with RC risk were found in the absence of MetS. Table [5](#Tab5){ref-type="table"} displays gene-environment interaction effects between *VEGF* 3′-UTR polymorphisms and MetS. We examined all possible combinations of gene-environment interactions using MDR methods. The combination of *VEGF* 1451C \> T and MetS was the best model to evaluate RC risk (Cross validation consistency = 9/10), while the combination of *VEGF* 1725G \> A and MetS was the most appropriate model to assess CC risk (Cross validation consistency = 7/10). The interaction of *VEGF* 1451C \> T and MetS contributed to increased RC risk (AOR = 3.15; 95% CI = 1.74 - 5.70; *p* \< .001) whereas the combination of *VEGF* 1725G \> A and MetS was involved with elevated CC risk (AOR = 2.68; 95% CI =1.30 - 1.55; *p* = 0.008).Table 4**Stratified effects of metabolic syndrome on colon cancer and rectal cancer risks by** ***VEGF*** **3′-UTR variants**CC riskRC riskGenotype/HaplotypeModelSubgroupWild typeAOR (95% CI)***p***AOR (95% CI)***p****VEGF* 1451C \> TAdditiveWithout MetSCC1.12 (0.80 - 1.54)0.5131.42 (0.99 - 2.03)0.055With MetSCC0.89 (0.50 - 1.59)0.7011.44 (0.77 - 2.67)0.255DominantWithout MetSCC1.18 (0.79 - 1.77)0.4161.67 (1.07 - 2.61)0.023With MetSCC0.78 (0.41 - 1.49)0.4561.44 (0.74 - 2.78)0.280RecessiveWithout MetSCC0.99 (0.41 - 2.40)0.9851.09 (0.41 - 2.87)0.868With MetSCC3.07 (0.30 - 31.00)0.3422.14 (0.13 - 35.71)0.595*VEGF* 1612G \> AAdditiveWithout MetSGG0.73 (0.49 - 1.07)0.1050.81 (0.53 - 1.24)0.328With MetSGG1.10 (0.61 - 2.02)0.7460.97 (0.50 - 1.87)0.928DominantWithout MetSGG0.71 (0.46 - 1.09)0.1170.69 (0.42 - 1.14)0.148With MetSGG1.13 (0.60 - 2.14)0.7040.93 (0.46 - 1.89)0.850RecessiveWithout MetSGG0.58 (0.15 - 2.17)0.4161.51 (0.49 - 4.61)0.469With MetSGG0.78 (0.05 - 13.40)0.8671.72 (0.10 - 28.53)0.705*VEGF* 1725G \> AAdditiveWithout MetSGG1.34 (0.72 - 2.49)0.3601.82 (0.95 - 3.48)0.072With MetSGG1.37 (0.62 - 2.98)0.4351.20 (0.51 - 2.85)0.672DominantWithout MetSGG1.34 (0.72 - 2.49)0.3601.82 (0.95 - 3.48)0.072With MetSGG1.37 (0.62 - 2.98)0.4351.20 (0.51 - 2.85)0.672RecessiveWithout MetSGG\-\-\--With MetSGG\-\-\--*VEGF* 1451C/1612G/1725GWithout MetSOthers1.06 (0.80 - 1.40)0.6970.87 (0.63 - 1.19)0.375With MetSOthers0.95 (0.61 - 1.49)0.8400.80 (0.50 - 1.28)0.354*VEGF* 1451T/1612G/1725GWithout MetSOthers1.13 (0.80 - 1.58)0.4951.45 (1.00 - 2.09)0.047With MetSOthers0.90 (0.51 - 1.58)0.7051.36 (0.77 - 2.42)0.292*VEGF* 1451C/1612A/1725GWithout MetSOthers0.61 (0.38 - 0.97)0.0380.48 (0.26 - 0.86)0.015With MetSOthers1.04 (0.48 - 2.25)0.9300.87 (0.37 - 2.08)0.760*VEGF* 1451C/1612A/1725AWithout MetSOthers1.09 (0.58 - 2.05)0.7951.75 (0.93 - 3.28)0.081With MetSOthers1.13 (0.53 - 2.43)0.7451.08 (0.47 - 2.51)0.854Adjusted odds ratio (AOR), Confidence interval (CI), Metabolic syndrome (MetS), Colon cancer (CC), Rectal cancer (RC), Vascular endothelial growth factor (VEGF). AORs and *p* values were adjusted by age and gender.Table 5**Combined effects of metabolic syndrome and** ***VEGF*** **3′-UTR variants on colon cancer and rectal cancer risks**CC riskRC riskWithout MetSWith MetSWithout MetSWith MetSGenotypeAOR (95% CI)***p***AOR (95% CI)***p***AOR (95% CI)***p***AOR (95% CI)***p****VEGF* 1451CC1.00 (reference)2.17 (1.43 - 3.28)\<.0011.00 (reference)2.22 (1.38 - 3.57)0.001*VEGF* 1451CT+TT1.18 (0.79 - 1.77)0.4161.76 (0.98 - 3.16)0.0601.67 (1.07 - 2.61)0.0233.15 (1.74 - 5.70)\<.001*VEGF* 1612GG1.00 (reference)1.68 (1.12 - 2.53)0.0131.00 (reference)1.94 (1.24 - 3.01)0.003*VEGF* 1612GA+AA0.71 (0.46 - 1.09)0.1171.81 (1.03 - 3.19)0.0400.69 (0.42 - 1.14)0.1481.66 (0.88 - 3.15)0.117*VEGF* 1725GG1.00 (reference)1.88 (1.29 - 2.73)0.0011.00 (reference)2.17 (1.44 - 3.27)\<.001*VEGF* 1725GA+AA1.34 (0.72 - 2.49)0.3602.68 (1.30 - 5.55)0.0081.82 (0.95 - 3.48)0.0722.49 (1.11 - 5.57)0.027Adjusted odds ratio (AOR), Confidence interval (CI), Metabolic syndrome (MetS), Colon cancer (CC), Rectal cancer (RC), Vascular endothelial growth factor (VEGF). AORs and *p* values were adjusted by age and gender.

Finally, we quantified expression of VEGF in tissue samples and looked for differences in expression based on the tested haplotypes and genotypes. VEGF expression as a function of each *VEGF* 3′-UTR genotype or haplotype is presented in Table [6](#Tab6){ref-type="table"}. Relative VEGF mRNA levels in samples with the 1451T/1612G/1725G were significantly decreased relative to the 1451C/1612G/1725G (*p \<* .05). In contrast, relative VEGF mRNA levels in samples with the 1451C/1612A/1725A were significantly increased from levels in samples with the 1451C/1612G/1725G (*p \<* .05). Table [7](#Tab7){ref-type="table"} shows VEGF expression between tumor and tumor-adjacent tissues according to studied polymorphisms. Relative VEGF mRNA expression of tumor-tissues is significantly increased in each wild genotype while not in each variant genotype. (Additional file [1](#MOESM1){ref-type="media"}: Table S1) displays the frequencies of MetS and *VEGF* 3′-UTR genotypes according to clinicopathological features of CRC. The frequency of *VEGF* 1451C \> T was different between the CC and RC groups, but this difference was not statistically significant (*p =* 0.081).Table 6***VEGF*** **mRNA expression levels (mean ± SE) according to** ***VEGF*** **3′-UTR genotypes and haplotypes**Tumor-adjacent (n = 47)***p***Tumor (n = 47)***p****VEGF* 1451CC (n = 32)1.00 ± 0.450.4451.00 ± 0.470.158*VEGF* 1451CT+TT (n = 15)2.54 ± 2.130.02 ± 0.01*VEGF* 1612GG (n = 33)1.00 ± 0.540.0081.00 ± 0.670.156*VEGF* 1612GA+AA (n = 14)6.76 ± 4.243.67 ± 2.38*VEGF* 1725GG (n = 41)1.00 ± 0.400.0381.00 ± 0.580.011*VEGF* 1725GA+AA (n = 6)5.98 ± 4.307.61 ± 5.43*VEGF* 1451C/1612G/1725G (n = 61)1.00 ± 0.350.0641.00 ± 0.390.027*VEGF* 1451T/1612G/1725G (n = 18)2.61 ± 2.190.02 ± 0.01*VEGF* 1451C/1612A/1725G (n = 9)2.72 ± 1.520.44 ± 0.42*VEGF* 1451C/1612A/1725A (n = 5)7.92 ± 6.084.59 ± 3.28Standard error (SE), Vascular endothelial growth factor (VEGF). *p* values were calculated by Mann--Whitney and Kruskal-Wallis tests.Table 7***VEGF*** **mRNA expression (mean ± SE) between tumor and tumor-adjacent tissues according to** ***VEGF*** **3′-UTR genotypes and haplotypes**Tumor-adjacent (n = 47)Tumor (n = 47)***p****VEGF* 1451CC (n = 32)1.00 ± 0.4575.37 ± 35.420.029*VEGF* 1451CT+TT (n = 15)1.00 ± 0.840.59 ± 0.300.125*VEGF* 1612GG (n = 33)1.00 ± 0.5452.24 ± 35.000.001*VEGF* 1612GA+AA (n = 14)1.00 ± 0.6328.36 ± 18.390.143*VEGF* 1725GG (n = 41)1.00 ± 0.4030.65 ± 17.780.011*VEGF* 1725GA+AA (n = 6)1.00 ± 0.7239.00 ± 27.830.203*VEGF* 1451C/1612G/1725G (n = 61)1.00 ± 0.3567.56 ± 26.35\<.001*VEGF* 1451T/1612G/1725G (n = 18)1.00 ± 0.810.50 ± 0.250.133*VEGF* 1451C/1612A/1725G (n = 9)1.00 ± 0.5610.93 ± 10.430.481*VEGF* 1451C/1612A/1725A (n = 5)1.00 ± 0.7739.15 ± 27.980.210Standard error (SE), Vascular endothelial growth factor (VEGF). *p* values were calculated by Wilcoxon signed rank test.

Discussion {#Sec9}
==========

In the present study, we investigated whether *VEGF* 1451C \> T, 1612G \> A, and 1725G \> A are involved with CRC susceptibility. We identified that *VEGF* 1451C \> T was significantly associated with RC risk whereas *VEGF* 1725G \> A correlated with MetS risk. Of the gene-environment combined effects, the interaction of *VEGF* 1451C \> T and MetS contributed to increased RC risk whereas the combination of *VEGF* 1725G \> A and MetS was involved with elevated CC risk. Furthermore, quantitative real-time PCR analysis revealed that relative VEGF mRNA expression in tumor tissues varied with *VEGF* 1451T/1612G/1725G and 1451C/1612A/1725A haplotypes. To our knowledge, *VEGF* 1451C \> T and 1725G \> A may play roles in CRC susceptibility.

Polymorphisms within the *VEGF* gene are a current topic of interest within the cancer epidemiology field. There are several association studies showing that *VEGF* -2578C \> A, -1498T \> C (-460T \> C), -1154G \> A, -634G \> C (405G \> C), and 936C \> T correlate with CRC risk \[[@CR6]\], and the following alleles: *VEGF* -2578A, -1498T, -1154A, -634C, and 936T: are associated with reduced VEGF expression \[[@CR25]--[@CR27]\]. Increased CRC incidence seems to occur in genotypes that cause both low (*VEGF* -2578A and 936T) and high (*VEGF* -1498C and -634G) VEGF expression \[[@CR24], [@CR28], [@CR29]\].

Angiogenesis under physiological conditions is a strictly regulated process on many levels, including spatial and temporal expression of genes, as well as intensity of the cellular response. Indeed, in the adult body, angiogenesis is constantly suppressed; the levels of anti-angiogenic molecules predominate in every tissue. However, failure of the regulatory processes that inhibit angiogenesis leads to the excessive generation of blood vessels that participate in cancer progression \[[@CR30]\]. Higher VEGF expression can increase tumor-related angiogenesis and metastasis \[[@CR31]\]. The role of angiogenesis as a prognostic factor of carcinogenesis and cancer progression, however, is still controversial \[[@CR32], [@CR33]\]. Weidner et al. \[[@CR3]\] first reported a direct correlation between the incidence of metastasis and the number and density of blood vessels in invasive breast carcinomas. Similar studies have made this association in gastrointestinal \[[@CR34]\] and colorectal cancers \[[@CR32], [@CR35]--[@CR39]\]. An association between elevated angiogenesis and both a high prevalence of metastases and a subsequent decrease in survival has been reported for a vast majority of solid tumors \[[@CR32], [@CR35]--[@CR39]\]. Several studies have revealed high angiogenic activity in CRC, which was more likely correlated with aggressive histological and pathological characteristics including parietal invasion, tumor stage, grade of tumor differentiation, metastatic rates, and poor survival rates \[[@CR32], [@CR40], [@CR41]\]. Also, Gurzu et al. \[[@CR32]\] reported that augmented levels angiogenesis in CRC were higher during early stages of tumor proliferation, but did not progressively increase as the tumors advanced. For these reasons, anti-angiogenesis is one possible target for cancer prevention and therapy.

However, anti-angiogenesis can induce the metastatic potential of cancer. Inhibition of VEGF/VEGF receptor (VEGFR) signaling causes a decrease in nutrient and oxygen levels, inducing hypoxia \[[@CR42]\]. One of the crucial steps in the cellular response to hypoxia is the stabilization of hypoxia-inducible factor (HIF)-1 in low-oxygen conditions. As a consequence, genes directly regulated by this transcription factor are activated. Because HIF-1 modulates the transcription of genes involved in glycolytic metabolism, oxygen consumption, survival, angiogenesis, migration, and invasion, its stabilization has a dramatic impact on the gene expression profile and ultimately on the behavior of the cells \[[@CR43]\]. For example, cancer cells react to the hypoxia caused by anti-angiogenic signals by reprogramming their metabolism, thus increasing the uptake of glucose to sustain energy production through glycolysis. This phenomena is referred to as the Warburg effect \[[@CR43]\]. Also, the epithelial-mesenchymal transition when stabilized HIF-1 transactivates the *Met* proto-oncogene, the receptor for hepatocyte growth factor \[[@CR44]\]. In addition, recent data suggest that VEGF supplementation may inhibit invasion and epithelial-mesenchymal transition of cancer cells \[[@CR45]\]. Therefore, for cancer prevention and therapy, it may be important to keep VEGF expression levels within a normal range. Previous reports showed that polymorphic events affecting the mRNA expression of *VEGF* and *VEGFR* genes could contribute to the survival duration of cancer patients receiving anti-angiogenic treatment \[[@CR46]--[@CR49]\]. The *VEGF* -2578A/-1498C/-634G haplotype showed a shorter survival time in multiple myeloma patients treated with thalidomide \[[@CR46]\]. The progression-free survival duration of metastatic renal cell carcinoma patients who received bevacizumab treatment varied between *VEGFR1* rs7993418 alleles \[[@CR47]\]. *VEGF* -2578CC, -1498TT, and -634CC were associated with a poorer prognosis and progression-free survival duration in advanced renal cell carcinoma patients receiving first-line sunitinib \[[@CR48]\]. *VEGF* -634CC displayed relatively shorter progression free survival duration in advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide \[[@CR49]\].

We identified an association between lower mRNA expression and RC risk in the *VEGF* 1451T carrier. Moreover, *VEGF* 1451T carrier combined with MetS was linked to increased RC risk, whereas the combination of higher mRNA expression in the *VEGF* 1725A carrier and MetS was linked to elevated CC risk. *VEGF* 1451T carrier could directly contribute to RC risk, but the *VEGF* 1725A allele could not have influence on CC risk alone. In other studies, weakened VEGF/VEGFR signaling was shown to cause a decrease in oxygen levels, and the HIF-1 transcription factor is stabilized in insulin resistance conditions \[[@CR42], [@CR50]\]. We hypothesize that low oxygen conditions in *VEGF* 1451T carrier and HIF-1 activation in MetS patients may lead to early cancer development. Activated HIF-1 drives the transcription of over 60 genes that are involved in cancer biology, including angiogenesis, cell survival, and glucose metabolism \[[@CR51]\]. *VEGF* 1725A carrier may influence a pathological angiogenesis step after persistent HIF-1 activation.

Genetic variation in the 3′-UTR region could affect the stability and translation of the mRNA through altered miRNA binding affinity. Currently, there are no data to directly show altered miRNA binding activity depending on *VEGF* 3′-UTR polymorphisms. Further studies are needed to directly test for miRNA binding activity to *VEGF* 3′-UTR polymorphisms to determine the mechanism by which these polymorphisms may influence cellular proliferation and cancer progression. These studies may have great clinical impact for all diseases related to abnormal angiogenesis and hypoxic conditions.

There are several limitations in this study. First, the mechanism by which 1451C \> T, 1612G \> A, and 1725G \> A polymorphisms in the *VEGF* gene affect development of CRC is still unclear. Further studies of whole *VEGF* sequence variants and their biological functions would uncover the role of these *VEGF* polymorphisms and haplotypes in the development and progression of CRC. Second, the present study lacked information regarding additional environmental risk factors (smoking, alcohol intake, caffeine intake, red meat intake, and multivitamin use) and clinical characteristics (survival time, relapse, death, chemotherapy, and radiotherapy) in the CRC patient cohort. These factors may contribute to overall CRC risk. Lastly, the population of this study was restricted to patients of Korean ethnicity. Because frequencies of genetic polymorphisms often vary between ethnic groups, more studies in diverse ethnic populations are warranted to clarify the association between *VEGF* 3′-UTR polymorphisms and CRC.

Conclusion {#Sec10}
==========

We investigated the involvement of *VEGF* polymorphisms 1451C \> T, 1612G \> A, and 1725G \> A with CRC susceptibility in the present study. *VEGF* 1451C \> T and 1725G \> A could contribute to CRC susceptibility when combined with the presence of MetS. Moreover, VEGF mRNA expression varied in tumor tissues depending on the combination of 3′-UTR polymorphic alleles present. Although results from our study provide the first evidence for *VEGF* 1451C \> T, 1612G \> A, and 1725G \> A as potential biomarkers for CRC prevention, a prospective study on a larger cohort of patients is warranted to validate these findings.
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